Professor of Medicine, UCLA
Hematology
Dr. John A. Glaspy, MD
|
|
Give Review
John Glaspy is an expert in the field of Hematology. She studied medicine at David Geffen School of Medicine at UCLA. David Geffen School of Medicine at UCLA is a one of the best medicals schools. David Geffen School of Medicine at UCLA has a rank of 13 in research and a 7 in primary care She has 6 awards "America's Top Doctors", "Top Doctors:LA Area", "America's Top Doctors for Cancer", "Top Doctors:Southern California", "Redbook Magazine: Top Breast Cancer Doctors" and "Super Doctor". John Glaspy is a published doctor. She has 49 papers published. The most current publication "PD-1 blockade induces responses by inhibiting adaptive immune resistance." She is registered with Medicare and accepts Medicare payments.
Publications
- PD-1 blockade induces responses by inhibiting adaptive immune resistance.
- Current status of use of erythropoietic agents in cancer patients.
- The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics.
- CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans.
- Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations.
- Darbepoetin alfa controversies, from dosage issues to safety concerns: the larger lesson.
- Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway.
- Randomized controlled trials of the erythroid-stimulating agents in cancer patients.
- Do we need a different set of response assessment criteria for tumor immunotherapy?
- Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.
- Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with che...
- Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter s...
- Erythropoietin in cancer patients.
- Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade.
- Erythropoiesis-stimulating agents in oncology.
- High-molecular weight iron dextran: a wolf in sheep's clothing?
- Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.
- Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomize...
- Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma.
- Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2.
- A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides.
- Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade).
- Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays.
- Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
- Cancer patient survival and erythropoietin.
- Every-three-week erythropoietic support during chemotherapy for cancer: current status and future issues.
- Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia.
- Entering a new era in the management of tumor-associated involution.
- Novel interactions of vitamin E and estrogen in breast cancer.
- Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy.
- Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma.
- Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells.
- T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer.
- Hematopoietic management in oncology practice. Part 2. Erythropoietic factors.
- Hematopoietic management in oncology practice. Part 1. Myeloid growth factors.
- Hemoglobin increase is associated with improved health-related quality of life in patients with cancer not receiving chemotherapy.
- Current developments in cancer vaccines and cellular immunotherapy.
- A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for maligna...
- Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma.
- Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion.
- Fatty acid modulation of MCF-7 human breast cancer cell proliferation, apoptosis and differentiation.
- Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy.
- The potential for anemia treatment to improve survival in cancer patients.
- Overcoming barriers to erythropoietic therapy. Characteristics of darbepoetin alfa and potential advances in scheduling, dosing, and dose-efficiency.
- Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.
- Standards of care for anemia management in oncology: focus on lung carcinoma.
- Therapeutic options in the management of renal cell carcinoma.
- Long-chain n-3-to-n-6 polyunsaturated fatty acid ratios in breast adipose tissue from women with and without breast cancer.
Doctors Specialties
- Hematology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:LA Area
- America's Top Doctors for Cancer
- Top Doctors:Southern California
- Redbook Magazine: Top Breast Cancer Doctors
- Super Doctor
Education
-
UCLA Medical Center -
David Geffen School of Medicine at UCLA
Hospital
-
Ronald Reagan UCLA Medical Center -
Santa Monica-UCLA Medical Center and Orthopaedic Hospital
Drug Facts
| NPI NUMBER | 1639104250 | |
| NPPES Provider LastName | GLASPY | |
| NPPES Provider FirstName | JOHN | |
| NPPES Provider ZIPCode | 900950001 | |
| NPPES Provider State | CA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 543.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1639104250 |
| Last Name Of The Provider | GLASPY |
| First Name Of The Provider | JOHN |
| View All |
Similar Doctors
|
Dr. Leo E. Orr, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Marjorie L. Bernstein-Singer, MD |
|
|
Dr. Akil A. Merchant, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Patrick Y. Chun, MD
This Doctor is OpenDoctor Recommended.
|
|
|
William P. Sheridan |